ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
Total Valuation
ImmunoCellular Therapeutics has a market cap or net worth of $19.24M. The enterprise value is $20.98M.
Market Cap$19.24M
Enterprise Value$20.98M
Share Statistics
ImmunoCellular Therapeutics has 113,270,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,270,750
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ImmunoCellular Therapeutics’s return on equity (ROE) is 0.80 and return on invested capital (ROIC) is 287.57%.
Return on Equity (ROE)0.80
Return on Assets (ROA)-19.33
Return on Invested Capital (ROIC)287.57%
Return on Capital Employed (ROCE)1.70
Revenue Per Employee0.00
Profits Per Employee-640.85K
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmunoCellular Therapeutics is ―. ImmunoCellular Therapeutics’s PEG ratio is 0.64.
PE Ratio―
PS Ratio0.00
PB Ratio-3.75
Price to Fair Value-3.75
Price to FCF-6.01
Price to Operating Cash Flow-14.40
PEG Ratio0.64
Income Statement
In the last 12 months, ImmunoCellular Therapeutics had revenue of 0.00 and earned -1.92M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit0.00
Operating Income-1.83M
Pretax Income-1.92M
Net Income-1.92M
EBITDA-1.83M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -688.49K and capital expenditures 0.00, giving a free cash flow of -688.49K billion.
Operating Cash Flow-688.49K
Free Cash Flow-688.49K
Free Cash Flow per Share>-0.01
Dividends & Yields
ImmunoCellular Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.36
52-Week Price Change13.42%
50-Day Moving Average0.15
200-Day Moving Average0.12
Relative Strength Index (RSI)54.45
Average Volume (3m)9.99K
Important Dates
ImmunoCellular Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
ImmunoCellular Therapeutics as a current ratio of 0.08, with Debt / Equity ratio of -73.45%
Current Ratio0.08
Quick Ratio0.08
Debt to Market Cap0.20
Net Debt to EBITDA-0.95
Interest Coverage Ratio-19.24
Taxes
In the past 12 months, ImmunoCellular Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ImmunoCellular Therapeutics EV to EBITDA ratio is -5.86, with an EV/FCF ratio of -7.17.
EV to Sales0.00
EV to EBITDA-5.86
EV to Free Cash Flow-7.17
EV to Operating Cash Flow-7.17
Balance Sheet
ImmunoCellular Therapeutics has $613.24K in cash and marketable securities with $3.47M in debt, giving a net cash position of -$2.85M billion.
Cash & Marketable Securities$613.24K
Total Debt$3.47M
Net Cash-$2.85M
Net Cash Per Share-$0.03
Tangible Book Value Per Share-$0.02
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ImmunoCellular Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―